時代天使(06699.HK)向合夥企業CareCapital額外增資1.2億元
時代天使(06699.HK)公布關連交易,與控股股東松柏投資集團最終控制的CC Founder Holdings LLC訂立經修訂合夥協議,雙方額外增加於合夥企業CareCapital Aligner Tech L.P.出資1.2億港元及1,200萬港元的美元等值金額。
公司指出,合夥企業旨在投資全球數字化正畸價值鏈中的創新數字化技術及產品。通過松柏投資集團在全球牙科領域建立的網絡資源,公司在數字化正畸行業看到更多投資和併購的機會。
此外,公司認為增資可使合夥企業於全球數字化正畸行業中謀求更多的投資機會,並通過進一步擴大其於整個產業價值鏈上的業務範圍及協同效應,使公司從投資中獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.